Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
29 30 Next >
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
3 Healthcare Stocks That Could Go Parabolic
These beaten-down stocks are ready for a rebound. 
Via The Motley Fool
Why Shares of CRISPR Therapeutics Dropped 19.9% in October
Several factors weighed on the gene-editing biotech stocks last month. 
Via The Motley Fool
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
Don't overlook these major healthcare names on your next stock-buying spree. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
Where CRISPR Therapeutics Stands With Analysts
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for CRISPR Therapeutics
Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
These two companies have performed almost equally poorly on the stock market in the past year. 
Via The Motley Fool
2 Monster Stocks to Buy Without Any Hesitation
These stocks are crushing the bear market. 
Via The Motley Fool
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
Vertex and LNG play Cheniere Energy are setting up bullishly. 
Via Investor's Business Daily
The Top 5 Stocks Cathie Wood Bought and Sold This Week
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
2 Budding Growth Stocks That Could Turn $1,000 Into $10,000 in 8 Years
They're both using unique and highly efficient approaches to developing and deploying their medicines. 
Via The Motley Fool
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
2 Under-the-Radar Biotech Stocks to Buy in 2022
These two drugmakers are growing in prominence. 
Via The Motley Fool
3 Cathie Wood Stocks to Buy and Hold for 10 Years
The risks are formidable, but the chances of a massive gain are too much to pass up. 
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
My Best Stocks to Buy Now and Hold Forever
These are ideal "forever" stocks. 
Via The Motley Fool
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold
Vertex already generates billions in revenue -- but there may be more to come. 
Via The Motley Fool
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics
Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter: 
Via Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
Upgrades 
Via Benzinga
2 Cathie Wood Stocks That Are Beating the Market This Year
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
Exposures Product Safety
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash. 
Via Benzinga
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market
Vertex flashed a buy signal on positive gene-editing news. 
Via Investor's Business Daily
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.